Journals / Anadolu Kardiyoloji Dergisi / 2008 / Cilt: 8 - Sayı: 1

Koroner ve serebrovasküler aterosklerozlu Türk hastalarda apolipoprotein B-3500 mutasyonu yokluğu

Absence of apolipoprotein B-3500 mutation in Turkish patients with coronary and cerebrovascular atherosclerosis

Pages
7–9
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: As it is hypothesized that this mutation arose within the Central European region from a common ancestor approximately 7000 years ago and spread across Europe, our result of the absence of the R3500Q mutation in Turkish patients give an important information about the geographical distribution of the apo B-R3500Q, that the mutation has not reached to Anatolia.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The arginine- to-glutamine change at codon 3500 of the apolipoprotein B-100 (apo B) is a well- known genetic cause of hypercholesterolemia.
📊
Key Findings & Data:Since increased cholesterol levels lead to atherosclerosis, identification of the carries of the apo B-3500 mutation is an important step in the risk stratification of individuals and families with hypercholesterolemia.
💡
Conclusion & Impact:Conclusion: As it is hypothesized that this mutation arose within the Central European region from a common ancestor approximately 7000 years ago and spread across Europe, our result of the absence of the R3500Q mutation in Turkish patients give an important information about the geographical distribution of the apo B-R3500Q, that the mutation has not reached to Anatolia.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The arginine- to-glutamine change at codon 3500 of the apolipoprotein B-100 (apo B) is a well- known genetic cause of hypercholesterolemia. Since increased cholesterol levels lead to atherosclerosis, identification of the carries of the apo B-3500 mutation is an important step in the risk stratification of individuals and families with hypercholesterolemia. The prevalence of this mutation in Turkish population is not well known. We aimed to investigate the frequency of apo B-100 mutations (codon 3500) C9774T (Arg 3500ÆTrp) and G9775A (Arg 3500ÆGln) in patients with atherosclerosis in comparison with healthy subjects.Methods: This cross-sectional study included 442 unrelated subjects living on the West coast of Turkey. Subgroups consisted of 165 patients with coronary artery disease, 163 patients with ischemic stroke, and 114 healthy control subjects.Results: We did not find any apo B-100 mutation both in the patient and control groups. Conclusion: As it is hypothesized that this mutation arose within the Central European region from a common ancestor approximately 7000 years ago and spread across Europe, our result of the absence of the R3500Q mutation in Turkish patients give an important information about the geographical distribution of the apo B-R3500Q, that the mutation has not reached to Anatolia.

Özet

Amaç: Apolipoprotein B-100 (apo B)’ün 3500. kodonunda arginin yerine glutamin değişimi bilinen bir genetik hiperkolesterolemi nedenidir. Yüksek kolesterol düzeyleri ateroskleroza yol açtığından, apo B-100 mutasyonunu taşıyan bireylerin saptanması hiperkolesterolemili aile ve kişilerin risk mücadelesinde önemli bir basamağı teşkil etmektedir. Bu mutasyonun Türk toplumundaki prevalansı iyi bilinmemektedir. Bu çalışmada 2 farklı apo B-100 mutasyonunun (3500 kodondaki C9774T (Arg 3500ÆTrp) ve G9775A (Arg 3500ÆGln)) aterosklerozlu hastalardaki sıklığını sağlıklı bireylerle karşılaştırmalı olarak araştırmayı amaçladıkYöntemler: Bu kesitsel çalışmada Türkiye’nin batı kıyısında yaşayan ve kan bağı olmayan 442 kişi incelenmiştir. Koroner hastalığı olan 165 kişi, iskemik inme öyküsü olan 163 kişi ve 114 sağlıklı gönüllü çalışmanın alt gruplarını oluşturmuştur.Bulgular: Hem hastalarda, hem de kontrol grubunda hiç apo B-100 mutasyonu saptamadık.Sonuç: Bu mutasyonun yaklaşık 7 bin yıl önce orta Avrupa’da ortak bir atadan çıkıp tüm Avrupa’ya yayıldığı hipotezinden hareketle Türk hastalarda R3500Q apo B mutasyonunu saptamamış olmamız bu mutasyonun coğrafik dağılımı hakkında önemli bir bilgi vermektedir: Mutasyon henüz Anadolu’ya ulaşmamıştır.

🔖

Cite This Article

KAYIKÇIOĞLU, M., TOPÇUOĞLU, N., BİRAY, C., KOSOVA, B., SELVİ, N., EROĞLU, Z., KUMRAL, E. (2022). Koroner ve serebrovasküler aterosklerozlu Türk hastalarda apolipoprotein B-3500 mutasyonu yokluğu. Anadolu Kardiyoloji Dergisi, Cilt: 8 - Sayı: 1, 7–9. https://ajindex.com/articles/437029

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Brown MS, Goldstein JL. A receptor mediated pathway for cholesterol homeostasis. Science 1986; 232: 34-47
  2. Innerarity TL, Mahley RW, Weisgraber KH, Bersot TP, Krauss RM, Vega GL, et al. Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. J Lipid Res 1990; 31: 1337-49
  3. Tybjaerg-Hansen A, Humphries S. Familial defective apolipoprotein B-100: a single mutation that causes hypercholesterolemia and premature coronary artery disease. Atherosclerosis 1992; 96: 91-107
  4. Friedewald WT, Levy RI, Frederickson DS. Estimation of concentration of low density lipoprotein cholesterol in plasma, without the use preparative ultracentrifuge. Clin Chem 1972; 18: 499-502
  5. Myant NB. Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholesterolemia. Atherosclerosis 1993; 104: 1-18
  6. Defesche JC, Pricker KL, Hayden MR, Van Der Ende BE, Kastelein JP. Familial defective apolipoprotein B-100 is clinically indistinguishable from familial hypercholesterolemia. Arch Intern Med 1993; 153: 2349-56
  7. Tybjaerg-Hansen A, Steffensen R, Meinertz H, Schnohr P, Nordestgaard BG. Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease. N Engl J Med 1998; 338: 1577-84
  8. Miserez AR, Laager R, Chiodetti N, Keller U. High prevalence of familial defective apolipoprotein B-100 in Switzerland. J Lipid Res 1994; 35: 574-83
  9. Ludwig EH, McCarthy BJ. Haplotype analysis of the human apolipoprotein B mutation associated with familial defective apolipoprotein B100. Am. J. Human Genet 1990; 47: 712-20
  10. Fisher E, Gross W, Marz W. High prevalence of FDB3500 mutation in the Swiss population. Atherosclerosis 2000; 153. 519-21
  11. Tai DY, Pan JP, Lee-Chen GJ. Identification and haplotype analysis of apolipoprotein B-100 Arg3500ÆTrp mutation in hyperlipidemic Chinese. Clin Chem 1998; 44: 1659-65
  12. Horvath A, Ganev V. The mutation APOB-100 R3500Q in Eastern Europe. Atherosclerosis 2001; 156: 241-2
  13. Rauh G, Schuster H, Fischer J, Keller C, Wolfram G, Zollner N. Familial defective apolipoprotein B-100: haplotype analysis of the arginine (3500) glutamine mutation. Atherosclerosis. 1991; 88: 219-26
  14. Myant NB, Forbes SA, Day IN, Gallagher J. Estimation of the age of the ancestral arginine3500-->glutamine mutation in human apoB-100. Genomics 1997; 45: 78-87
  15. Miserez AR, Muller PY. Familial defective apolipoprotein B-100: